The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Over the last decade, a new understanding of tumor-immune system interplay has been ushered in, lead in large part by the discovery of immune checkpoints mediated through B7-CD28 family interactions. Therapeutic blockade of the PD-L1 immune checkpoint pathway has already shown great success as a cancer immunotherapy for advanced urothelial carcinoma, leading to durable clinical remissions in an otherwise incurable disease. There are newly described members of the B7-CD28 family including B7-H3, B7x, and HHLA2. These ligands are thought to play an essential role in suppressing T-cell response, leading to immune tolerance of tumors. This feature makes them attractive targets for novel immunotherapy treatment paradigms. Here, we review the literature of current strategies and future directions of immune checkpoint blockade therapy for bladder cancer.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
StateAccepted/In press - Dec 22 2016

Fingerprint

Urinary Bladder Neoplasms
Immunotherapy
Neoplasms
Immune Tolerance
Immune System
Therapeutics
Ligands
Carcinoma
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{bc27b72fe2dd4f43a0e5a4d3a946d711,
title = "The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1",
abstract = "Over the last decade, a new understanding of tumor-immune system interplay has been ushered in, lead in large part by the discovery of immune checkpoints mediated through B7-CD28 family interactions. Therapeutic blockade of the PD-L1 immune checkpoint pathway has already shown great success as a cancer immunotherapy for advanced urothelial carcinoma, leading to durable clinical remissions in an otherwise incurable disease. There are newly described members of the B7-CD28 family including B7-H3, B7x, and HHLA2. These ligands are thought to play an essential role in suppressing T-cell response, leading to immune tolerance of tumors. This feature makes them attractive targets for novel immunotherapy treatment paradigms. Here, we review the literature of current strategies and future directions of immune checkpoint blockade therapy for bladder cancer.",
author = "Sankin, {Alexander I.} and Deepa Narasimhulu and Peter John and Gartrell, {Benjamin A.} and Schoenberg, {Mark P.} and Xingxing Zang",
year = "2016",
month = "12",
day = "22",
doi = "10.1016/j.urolonc.2017.04.007",
language = "English (US)",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer

T2 - What lies beneath the tip of the iceberg, PD-L1

AU - Sankin, Alexander I.

AU - Narasimhulu, Deepa

AU - John, Peter

AU - Gartrell, Benjamin A.

AU - Schoenberg, Mark P.

AU - Zang, Xingxing

PY - 2016/12/22

Y1 - 2016/12/22

N2 - Over the last decade, a new understanding of tumor-immune system interplay has been ushered in, lead in large part by the discovery of immune checkpoints mediated through B7-CD28 family interactions. Therapeutic blockade of the PD-L1 immune checkpoint pathway has already shown great success as a cancer immunotherapy for advanced urothelial carcinoma, leading to durable clinical remissions in an otherwise incurable disease. There are newly described members of the B7-CD28 family including B7-H3, B7x, and HHLA2. These ligands are thought to play an essential role in suppressing T-cell response, leading to immune tolerance of tumors. This feature makes them attractive targets for novel immunotherapy treatment paradigms. Here, we review the literature of current strategies and future directions of immune checkpoint blockade therapy for bladder cancer.

AB - Over the last decade, a new understanding of tumor-immune system interplay has been ushered in, lead in large part by the discovery of immune checkpoints mediated through B7-CD28 family interactions. Therapeutic blockade of the PD-L1 immune checkpoint pathway has already shown great success as a cancer immunotherapy for advanced urothelial carcinoma, leading to durable clinical remissions in an otherwise incurable disease. There are newly described members of the B7-CD28 family including B7-H3, B7x, and HHLA2. These ligands are thought to play an essential role in suppressing T-cell response, leading to immune tolerance of tumors. This feature makes them attractive targets for novel immunotherapy treatment paradigms. Here, we review the literature of current strategies and future directions of immune checkpoint blockade therapy for bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=85019036423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019036423&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2017.04.007

DO - 10.1016/j.urolonc.2017.04.007

M3 - Article

C2 - 28495553

AN - SCOPUS:85019036423

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

ER -